MetaCap

Imunon (IMNN) vs Xenetic Biosciences (XBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Imunon is the larger company by market cap ($3.5 million vs $3.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMNN-53.03%XBIO-36.65%
+13%-22%-56%
Oct 7, 20261 yearNov 20, 2026
IMNN-50.42%XBIO-34.27%
+18%-18%-54%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMNN versus XBIO key metrics
MetricIMNNXBIO
Share price$0.5355$1.40
Market cap$3.47M$3.28M
1-day change-5.22%-9.09%
EPS (TTM)$-3.31$-1.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.98M
Revenue growth (YoY)—+19.04%
Net income (latest FY)$-14.50M$-2.68M
Operating margin—-95.23%
Net margin—-90.07%
52-week high$4.35$4.94
52-week low$0.50$1.25
Distance from 52-week high-87.69%-71.65%
Analyst consensusstrong_buy—
Avg. price target upside+3074.60%—
Average volume150.49K73.30K
Shares outstanding6.49M2.34M
Employees202
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Imunon

IMNN stock →

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

About Xenetic Biosciences

XBIO stock →

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

IMNN vs XBIO FAQ

Which is bigger, Imunon or Xenetic Biosciences?

Imunon (IMNN) is larger, with a market capitalization of $3.47M compared with $3.28M for Xenetic Biosciences (XBIO).

Are Imunon and Xenetic Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons